查詢結果分析
來源資料
相關文獻
- 心衰竭與慢性阻塞性肺病的新概念:臨床常見但是容易忽略的共病
- Correlation of the New GOLD Classification (2013 Version) with Exercise Capacity and Mortality Risk
- 出院準備服務 : 出院後不同照護模式的選擇、再入院率、死亡率的分析
- 心衰竭合併呼吸道疾病患者處方Beta-blockers案例之用藥建議及文獻探討
- 骨折聯合照護服務在髖部骨折病人成功經驗:有效的減少死亡率
- The Risks and Mortality of Dementia among General Population: A 10-Year Registration Study in Taiwan
- Factors Associated with One-year Mortality of Patients Receiving Home Healthcare Service in a Regional Hospital in Northern Taiwan
- 探討心臟衰竭患者實施限水措施是否能降低再住院率與死亡率之實證分析
- Comparison of the Outcome of Extremely-Low-Birth-Weight Infants between Two Periods
- 精神科專科醫院急性住院患者之死亡率
頁籤選單縮合
題 名 | 心衰竭與慢性阻塞性肺病的新概念:臨床常見但是容易忽略的共病=New Insight into Congestive Heart Failure and Chronic Obstructive Pulmonary Disease--A Common but Ignored Concomittant Disease |
---|---|
作 者 | 曾筱倫; 李文煌; 趙庭興; 薛仰哲; 黃耀毅; 李貽恆; 蔡良敏; | 書刊名 | 內科學誌 |
卷 期 | 22:1 2011.02[民100.02] |
頁 次 | 頁1-8 |
分類號 | 415.319、415.319 |
關鍵詞 | 心衰竭; 慢性阻塞性肺病; 共病; 死亡率; 再入院; Congestive heart failure; Chronic obstructive pulmonary disease; Concomitant disease; Mortality; Rehospitalization; |
語 文 | 中文(Chinese) |
中文摘要 | 心衰竭與慢性阻塞性肺病是造成急性呼吸衰竭最常見的原因。臨床上,這兩個疾病常常 共存,而且互為彼此預後之預測因子。但因為這兩個疾病有相似的臨床症狀與徵候,而且這 兩個疾病共存時會彼此遮蔽對方典型的表現,往往造成診斷上的困難,進而忽略了這兩個疾 病共存的事實。腦利鈉胜肽可以作為心衰竭與慢性阻塞性肺病急性惡化的鑑別診斷工具,如 果腦利鈉胜肽低於100 pg/mL 應可排除心衰竭急性惡化,而當腦利鈉胜肽高於500 pg/mL 時 則要高度懷疑心衰竭急性惡化。治療這個共病時也會因為擔心彼此的禁忌症而礙手礙腳,不 敢大膽的用藥。本文整理最近的文獻,針對共病之盛行率,彼此對預後的影響,診斷上的盲 點及治療上的兩難做深入的回顧。 |
英文摘要 | The coexistence of congestive heart failure and chronic obstructive pulmonary disease is common in patients with acute dyspnea. The frequency of coexistence is far beyond our imagination. Clinical diagnosis is difficult to make because they share common but nonspecific symptoms and signs. Brain natriuretic peptide (BNP) is a useful serum biomarker to differentiate acute exacerbation of congestive heart failure from chronic obstructive pulmonary disease. Acute exacerbation of congestive heart failure could be excluded if BNP level is less than 100 pg/mL. Acute exacerbation of congestive heart failure is highly suspected if BPN level is more than 500 pg/mL. Treatment of this common concomitant disease is usually suboptimal because of being afraid of their contra-indication. To the best of our knowledge, there is no large clinical trial regarding this issue so far. In this review, we try to highlight the comorbidity, prognostic impact, diagnostic confusion and therapeutic dilemma of both diseases. |
本系統中英文摘要資訊取自各篇刊載內容。